Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
LX-2020 by Lexeo Therapeutics for Cardiomyopathy: Likelihood of Approval
LX-2020 is under clinical development by Lexeo Therapeutics and currently in Phase II for Cardiomyopathy. According to GlobalData, Phase II...